ZHEJIANG HUAHAI PHARMACEUTICAL CO.,LTD.

Established in 2010 and headquartered in Linhai, China, Zhejiang Ausun Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of unique active pharmaceutical ingredients (APIs) and various intermediate compounds for drug synthesis. Its comprehensive portfolio includes fluorine-based compounds, prostaglandins, and anti-infectives, in addition to critical oncology therapeutics. The company also provides medications targeting liver, respiratory, cardiovascular, and cerebrovascular conditions, as well as central nervous system (CNS) disorders. Furthermore, Zhejiang Ausun Pharmaceutical is involved in contract processing services and continuous scientific research and development initiatives.

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, a company established in 1973 and operating from its headquarters in Taizhou, China, specializes in the production and global supply of active pharmaceutical ingredients (APIs) and their chemical precursors. Its extensive product catalog includes APIs designed for a wide range of therapeutic applications, encompassing treatments for central nervous system disorders (such as anti-depressants and Parkinson's disease), various infectious ailments (including antiviral, general anti-infection, and specific respiratory anti-infection agents), diabetes management, non-steroidal drugs, oncological therapies, Hepatitis C, and cardiovascular conditions. Furthermore, beyond its pharmaceutical focus, the company also furnishes specialized asymmetric catalysts and crucial materials utilized in lithium-ion batteries.

Zhejiang Hisun Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the development, manufacturing, and distribution of a broad spectrum of pharmaceutical products. Its portfolio includes both active pharmaceutical ingredients (APIs) and finished drug formulations. The company's extensive therapeutic focus spans oncology, cardiovascular health, infectious diseases, liver support, orthopedics, parasitic infections, and immunosuppression. Additionally, Hisun Pharmaceutical addresses conditions such as weight management, viral infections, tuberculosis, and offers veterinary pharmaceuticals, among other specialized medical applications. Beyond its product lines, the firm provides product consultation and contract manufacturing/research (CMO/CRO) services. Established in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is headquartered in Taizhou, China.

Established in 2008 and based in Beijing, China, Beijing Kawin Technology Share-Holding Co., Ltd. specializes in the research, development, and manufacturing of pharmaceutical products, with a primary emphasis on treatments for liver conditions within the Chinese market. Its key offerings include recombinant human interferon alfa-2b injection and compound glycyrrhizin. Beyond its own product line, the company supplies active pharmaceutical ingredients (APIs) and delivers comprehensive clinical research services for advancing biological products. These services encompass the fermentation and purification of drug substances, drug product formulation, and the creation of analytical methods. Beijing Kawin also offers contract manufacturing solutions. The company's global footprint includes serving customers in countries such as Pakistan, Colombia, the Philippines, Vietnam, Russia, and Cambodia, among others. Furthermore, it maintains strategic partnerships with entities like Legend Capital, Haitong Capital, and Cybernaut.

Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both prescription and over-the-counter (OTC) medications, and home-delivered medicines. These products are available in various formats, including tablets, capsules, lozenges, granules, and powdered forms. Beyond its own brand, the company also provides contract manufacturing services, developing medicinal formulations for other pharmaceutical firms. Additionally, Daito Pharmaceutical markets health food products. Established in 1942, it was initially known as Daito Corporation, changing to its current name in 1992, and maintains its headquarters in Toyama, Japan.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.